Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 81
- Registration Number
- NCT01435629
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 348
- Registration Number
- NCT01427920
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- HealthyDiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: I.v. NNC 0113-0987Drug: oral NNC 0113-0987Drug: oral placebo
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 101
- Registration Number
- NCT01405261
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4121
- Registration Number
- NCT01403025
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Growth DisorderHealthyPrader-Willi SyndromeIdiopathic Short StatureGenetic Disorder
- Interventions
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT01401244
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Evansville, Indiana, United States
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia B
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT01395810
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 413
- Registration Number
- NCT01392573
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, St. Gallen, Switzerland
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 72
- Registration Number
- NCT01392547
- Locations
- 🇵🇷
Novo Nordisk Clinical Trial Call Center, San Juan, Puerto Rico
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 413
- Registration Number
- NCT01388361
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia B
- Interventions
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 13
- Registration Number
- NCT01386528
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath